Navigation Links
Next Safety Releases Advanced Respirator for Infectious Diseases

JEFFERSON, N.C., Aug. 5 /PRNewswire/ -- Next Safety, Inc. (NSI) announces advanced respirators that give people more confidence to go to work in a pandemic environment. Next Safety is releasing for sale to the public respirator products the company developed for the bird flu influenza A subtype H5N1.

The respirators were originally developed for the bird flu (H5N1), which never became contagious. The Next Safety respirators are now being sold to the public for the first time. These respirators are a cross functional platform that supply highly purified air to half facemasks and air supply hoods.

Next Safety designed its respirators with input from the CDC and the World Health Organization along from the US army's famed AMRIID bioterrorism warfare center.

Next Safety's core competence is the development, design and rapid production of pulmonary products like its 9000 series respirators. Next Safety respirators are rated for 30,000 hours of continuous operation.

Next Safety respirator products are fabricated from battlefield-grade medical plastics. Next Safety uses compound filters that do not fail. Texas Instruments and EBM-Pabst power Next Safety's respirator products.

As with all respirator products, to be effective, Next Safety respirators must be used with proper eye protection and with a well-defined and understood decontamination program.

Next Safety is a leader in the development of pulmonary health products. It has a product line of advanced respirators that were developed for many different applications.

The company also develops pulmonary drug delivery products. It is a leader in the development of nicotine delivery devices for smoking cessation and nicotine replacement products.

Next Safety has 28 US patents that are either issued are pending for its products.

Next Safety is also developing other pulmonary drug delivery platforms for inhaled antibiotics and anti-medics, concentrated narcotics and drugs to treat pulmonary conditions such as asthma, COPD and the immune compromised.

The doctors, scientists and engineers who work for Next Safety have developed the most comprehensive and effective solution for the pulmonary delivery of medicines to in-home patients and persons who are addicted to smoking cigarettes. The company is developing combined respirator and pulmonary drug delivery systems for soldiers to have highly sophisticated medical care that greatly enhances their likely hood of survival in battle.

Next Safety engineers are experts in high-volume manufacturing. The company's engineers and managers have made more than 40 million electrical devices a month for years. These are products that are designed to protect babies and children.

Next Safety has invested in significant capacity for pandemic stockpiling. The company expects to build approximately 5 million respirators for delivery in December 2009 and has the capacity to build 300 million respirators a month for pandemic stockpiling by March 2010.

Next Safety thanks the doctors and staff at Italy's level-4 Milan biological research center for helping it design the best respirators for pandemic stockpiling.

Next Safety's advanced respirator product line is available at


    Eric Hunter

This release was issued through eReleases(TM). For more information, visit

SOURCE Next Safety, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Elagolix Successful in Six Month Lilac Petal Study; Safety and Efficacy Confirmed in Patients With Endometriosis
2. Improving Transfusion Safety: Fenwal, Verax Biomedical Sign Agreement for Rapid, Point-of-Care Bacteria Test
3. Inspiration Biopharmaceuticals Presents Safety Data on IB1001, a Novel Recombinant Factor IX for the Treatment of Hemophilia at the International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting
4. MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
5. EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements
6. AEterna Zentaris to Report Data from Safety Study of Phase 3 Program in Benign Prostatic Hyperplasia with Cetrorelix Ahead of Schedule
7. iCardiac Selected for Multiple Cardiac Safety Studies
8. Assessment of safety and efficacy of human embryonic stem cell therapy
9. Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients
10. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
11. Leaders in Health Literacy Recognized by the Partnership for Clear Health Communication at the National Patient Safety Foundation
Post Your Comments:
(Date:6/27/2016)... , June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ... advised by its major shareholders, Clean Technology Fund I, ... United States based venture capital funds which ... Biorem (on a fully diluted, as converted basis), that ... of their entire equity holdings in Biorem to TUS ...
(Date:6/27/2016)... ... ... Parallel 6 , the leading software as a service (SaaS) provider ... Patient Encounter CONSULT module which enables both audio and video telemedicine communication between the ... the CONSULT module, patients and physicians can schedule a face to face virtual patient ...
(Date:6/27/2016)... -- Liquid Biotech USA , Inc. ... Research Agreement with The University of Pennsylvania ("PENN") ... patients.  The funding will be used to assess ... outcomes in cancer patients undergoing a variety of ... to support the design of a therapeutic, decision-making ...
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
Breaking Biology Technology:
(Date:3/31/2016)... 2016  Genomics firm Nabsys has completed a financial ... Bready , M.D., who returned to the company in ... leadership team, including Chief Technology Officer, John Oliver ... Nurnberg and Vice President of Software and Informatics, ... Dr. Bready served as CEO of Nabsys from ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
(Date:3/22/2016)... , PROVO and ... -- Newborn Screening Ontario (NSO), which operates the highest ... for molecular testing, and Tute Genomics and UNIConnect, leaders ... technology respectively, today announced the launch of a project ... sequencing (NGS) testing panel. NSO has ...
Breaking Biology News(10 mins):